<DOC>
	<DOC>NCT00431613</DOC>
	<brief_summary>The combination of chemotherapy with radiotherapy remains the standard of therapy for patients with stage III NSCLC. A recent phase II study has presented encouraging data regarding the administration of docetaxel as consolidation treatment after definitive concurrent chemo-radiotherapy.</brief_summary>
	<brief_title>Study of Docetaxel/Gemcitabine Followed by Chemo-radiotherapy (Chemo-RT), With or Without Consolidation Chemotherapy, in IIIA/IIIB Non Small Cell Lung Cancer (NSCLC)</brief_title>
	<detailed_description>To evaluate whether the administration of consolidation therapy with docetaxel/carboplatin after induction chemotherapy followed by concurrent chemoradiotherapy, offers any advantage regarding time to tumor progression</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>histologically or cytologically confirmed, unresectable locally advanced (stage IIIA/IIIB) NSCLC no previous therapy for NSCLC is allowed age &gt;18 years bidimensionally measurable disease performance status (WHO) 02 absence of pleural effusion adequate liver (serum bilirubin &lt; 1.5 times the upper normal limit (UNL); AST and ALT &lt; 2.5 times the UNL in the absence of demonstrable liver metastases, or &lt; 5 times the UNL in the presence of liver metastases); adequate renal function (serum creatinine &lt; 1.5 times the UNL); and bone marrow (neutrophils ≥ 1.5x 109 /L, and platelets ≥ 100x 109 /L) function life expectancy of more than 3 months written informed consent active infection history of significant cardiac disease (unstable angina, congestive heart failure, myocardial infarction within the previous 6 months, ventricular arrhythmias) malnutrition (loss of ≥ 20% of the original body weight) performance status: 34 sensor or motor neuropathy &gt; grade I second primary malignancy, except for nonmelanoma skin cancer psychiatric illness or social situation that would preclude study compliance pregnant or lactating women</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>Induction chemotherapy</keyword>
	<keyword>Concurrent chemoradiotherapy</keyword>
	<keyword>Consolidation therapy</keyword>
	<keyword>Docetaxel</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Carboplatin</keyword>
</DOC>